Taysha Gene Therapies signs commercial supply deal with Catalent for TSHA-102 Rett syndrome therapy

• Taysha Gene Therapies signed a commercial supply agreement naming Catalent as primary commercial manufacturer for TSHA-102, its Rett syndrome gene therapy.
• Catalent will provide GMP manufacturing at its FDA-licensed gene therapy facility in Harmans, Maryland, contingent on FDA approval.
• Deal expands a partnership in place since 2020, securing long-term manufacturing capacity ahead of a potential U.S. launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.